이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Macular Edema After Retinal Vein Occlusion (MK-8748-006)

2026년 11월 16일 업데이트: Merck Sharp & Dohme LLC

Randomized, Double-Masked, Multicenter, 3 Arm, Pivotal Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal (IVT) MK-8748 Compared With Aflibercept (2 mg) in Participants With Macular Edema Following Retinal Vein Occlusion (ME-RVO)

Researchers are looking for new ways to treat macular edema after retinal vein occlusion (ME-RVO). ME-RVO happens when a vein becomes blocked in the retina, the back part of the eye. This blockage causes fluid to leak into the macula, which is the part of the retina that helps to see fine details. The buildup of fluid, called macular edema, can cause blurry vision.

In this trial, researchers want to learn if a trial medicine called MK-8748 can treat ME-RVO. A standard (usual) treatment for ME-RVO is aflibercept. However, standard treatments such as aflibercept may not work for every person.

The main goal of this trial is to learn if participants who receive MK-8748 can see as clearly as participants who receive aflibercept.

연구 개요

상태

아직 모집하지 않음

정황

개입 / 치료

연구 유형

중재적

등록 (추정된)

1188

단계

  • 2 단계
  • 3단계

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

The main inclusion criteria include but are not limited to the following:

  • Has a diagnosis of macular edema following retinal vein occlusion (ME-RVO) within 4 months (120 days) before screening and is treatment-naïve for ME-RVO
  • Has a BCVA ETDRS letter score between 73 and 19 (20/40 - 20/400 Snellen equivalent), inclusive, in the study eye at screening. In the event that both eyes are eligible, the worst-seeing eye should be enrolled in the trial.
  • Has a decrease in vision in the study eye determined by the investigator to be primarily the result of ME-RVO.

The main exclusion criteria include but are not limited to the following:

  • Has history of stroke (cerebral vascular accident) or myocardial infarction within 180 days prior to study entry
  • Has any active malignancy, except non-melanoma skin carcinoma.
  • Has history of previous episodes of ME-RVO or persistent ME-RVO diagnosed more than 4 months before screening
  • Has any prior steroid implant use including dexamethasone intravitreal implant (Ozurdex®) and fluocinolone acetonide intravitreal implant (Iluvien®) or other intraocular or periocular corticosteroids in the study eye at any time.
  • Has prior periocular pharmacological or intravitreal treatment (including anti-vascular endothelial growth factor medication) for other retinal diseases in the study eye at any time.
  • Has a history of cataract surgery and/or minimally invasive glaucoma surgery in the study eye within 90 days of screening.
  • Has significant active retinal disease (ie, moderate non-proliferative diabetic retinopathy or worse, proliferative diabetic retinopathy, geographic atrophy, myopic choroidal neovascularization) other than the ME-RVO under investigation in the study eye.
  • Is currently using drugs with known retinal toxicity (eg, hydroxychloroquine, pentosan polysulfate sodium).

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 삼루타

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: MK-8748 low dose

Participants receive MK-8748 low dose every 4 weeks (Q4W) administered in the study eye until week 48. After week 48, participants will be treated at intervals determined based on individualized response to treatment, up to week 96.

Administered via intravitreal (IVT) injection

다른 이름들:
  • EYE201
실험적: MK-8748 High Dose

Participants receive MK-8748 high dose every 4 weeks (Q4W) administered in the study eye until week 48. After week 48, participants will be treated at intervals determined based on individualized response to treatment, up to week 96.

Administered via intravitreal (IVT) injection

다른 이름들:
  • EYE201
활성 비교기: Aflibercept 2 mg

Participants receive aflibercept 2 mg every 4 weeks (Q4W) administered in the study eye until week 48. After week 48, participants will be treated at intervals determined based on individualized response to treatment, up to week 96.

Administered via IVT injection

다른 이름들:
  • 아일리아

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Mean Change in Best-Corrected Visual Acuity (BCVA) (Early Treatment of Diabetic Retinopathy Study [ETDRS] Letters) From Baseline to Week 24
기간: Baseline and Week 24

Participants' BCVA in the study eye will be measured using the Early Treatment of Diabetic Retinopathy (ETDRS) methodology. The ETDRS letter score ranges from 0 to 100, with a higher score indicating better visual acuity. Mean change in ETDRS letters from baseline to week 24 will be assessed.

Baseline and Week 24

2차 결과 측정

결과 측정
측정값 설명
기간
Mean Change in Central Subfield Thickness (CST) from Baseline to Week 24
기간: Baseline and Week 24

Central subfield thickness (CST) in the study eye will be measured in microns using optical coherence tomography (OCT). The mean change in CST from baseline to week 24 will be presented.

Baseline and Week 24
Mean Change in CST from Baseline Over Time
기간: Up to approximately 96 weeks

Central subfield thickness (CST) in the study eye will be measured in microns using optical coherence tomography (OCT). The mean change in CST from baseline over time will be presented.

Up to approximately 96 weeks
Time to Absence of Diabetic Macular Edema (DME)
기간: Up to approximately 96 weeks

The absence of Diabetic Macular Edema (DME) is defined as a Central Subfield Thickness (CST) of <300 μm measured using optical coherence tomography (OCT). The time to absence of Diabetic Macular Edema (DME) in the study eye will be presented.

Up to approximately 96 weeks
Proportion of Participants with Absence of Intraretinal Fluid Over Time
기간: Up to approximately 96 weeks

Participants' intraretinal fluid in the study eye will be measured using optical coherence tomography (OCT). The proportion of participants with absence of intraretinal fluid over time will be presented.

Up to approximately 96 weeks
Proportion of Participants with Absence of Subretinal Fluid Over Time
기간: Up to approximately 96 weeks

Participants' subretinal fluid in the study eye will be measured using optical coherence tomography (OCT). The proportion of participants with absence of subretinal fluid over time will be presented.

Up to approximately 96 weeks
Proportion of Participants with Absence of Intraretinal Fluid and Subretinal Fluid Over Time
기간: Up to approximately 96 weeks

Participants' subretinal fluid and intraretinal fluid in the study eye will be measured using optical coherence tomography (OCT). The proportion of participants with absence of intraretinal and subretinal fluid over time will be presented.

Up to approximately 96 weeks
Proportion of Participants with Resolution of Macular Leakage on Fluorescein Angiography (FA) at Week 24
기간: Week 24

Fluorescein Angiography (FA) images will be used to determine the resolution of macular leakage in the study eye, defined as 0 to 1 mm^2. The proportion of participants with resolution of macular leakage at Week 24 will be presented.

Week 24
Proportion of Participants with Resolution of Macular Leakage on FA at Week 48
기간: Week 48

FA images will be used to determine the resolution of macular leakage in the study eye, defined as 0 to 1 mm^2. The proportion of participants with resolution of macular leakage at Week 48 will be presented.

Week 48
Proportion of Participants with Resolution of Macular Leakage on FA at Week 96
기간: Week 96

FA images will be used to determine the resolution of macular leakage in the study eye, defined as 0 to 1 mm^2. The proportion of participants with resolution of macular leakage at Week 96 will be presented.

Week 96
Mean Change in Vascular Leakage Area on FA in the Macula From Baseline Over Time
기간: Up to approximately 96 weeks

Vascular leakage area in the macula will be evaluated using FA images graded by a centralized reading center. The total area of macular vascular leakage will be measured in square millimeters (mm²). The mean change in vascular leakage area from baseline over time will be presented.

Up to approximately 96 weeks
Mean Change From Baseline in Macular Ischemic Nonperfusion Area as Assessed by Optical Coherence Tomography Angiography (OCT-A)
기간: Up to approximately 96 weeks

Macular ischemic nonperfusion area (defined as areas of capillary nonperfusion or capillary drop-out within the superficial and/or deep retinal capillary plexuses) is measured in square millimeters (mm²) using OCT-A. Images are analyzed and graded by a centralized, masked independent reading center. The mean change in ischemic nonperfusion area from baseline over time will be presented.

Up to approximately 96 weeks
Proportion of Participants Requiring Panretinal Photocoagulation
기간: Up to approximately 96 weeks

The proportion of participants requiring panretinal photocoagulation treatment will be presented.

Up to approximately 96 weeks
Mean Number of Intravitreal (IVT) Injections from Week 48 to Week 96
기간: Up to approximately 48 weeks

The mean number of intravitreal (IVT) Injections from week 48 to week 96 will be presented.

Up to approximately 48 weeks
Proportion of Participants on a Personalized Treatment Interval (PTI) of Every 4 Weeks (Q4W) at Week 96
기간: Up to approximately 96 weeks

The proportion of participants on a personalized treatment interval (PTI) of Q4W at Week 96 will be presented.

Up to approximately 96 weeks
Proportion of Participants on a Personalized Treatment Interval (PTI) of Every 8 Weeks (Q8W) at Week 96
기간: Up to approximately 96 weeks

The proportion of participants on a personalized treatment interval (PTI) of Q8W at Week 96 will be presented.

Up to approximately 96 weeks
Proportion of Participants on a Personalized Treatment Interval (PTI) of Every 12 Weeks (Q12W) at Week 96
기간: Up to approximately 96 weeks

The proportion of participants on a personalized treatment interval (PTI) of Q12W at Week 96 will be presented.

Up to approximately 96 weeks
Proportion of Participants on a Personalized Treatment Interval (PTI) of Every 16 Weeks (Q8W) at Week 96
기간: Up to approximately 96 weeks

The proportion of participants on a personalized treatment interval (PTI) of Q16W at Week 96 will be presented.

Up to approximately 96 weeks
Mean Change in BCVA (ETDRS letters) from Baseline Over Time
기간: Baseline and 96 weeks

Participants' BCVA in the study eye will be measured using the Early Treatment of Diabetic Retinopathy (ETDRS) methodology. The ETDRS letter score ranges from 0 to 100, with a higher score indicating better visual acuity. The mean change in BCVA (ETDRS) letters from baseline over time will be presented.

Baseline and 96 weeks
Proportion of Participants who Gain ≥5 ETDRS Letters from Baseline at Week 24
기간: Baseline and week 24

Participants' BCVA in the study eye will be measured using the Early Treatment of Diabetic Retinopathy (ETDRS) methodology. The ETDRS letter score ranges from 0 to 100, with a higher score indicating better visual acuity. The proportion of participants who gain ≥5 ETDRS letters from baseline to year 1 will be presented.

Baseline and week 24
Proportion of Participants who Gain ≥10 ETDRS Letters from Baseline at Week 24
기간: Baseline and week 24

Participants' BCVA in the study eye will be measured using the Early Treatment of Diabetic Retinopathy (ETDRS) methodology. The ETDRS letter score ranges from 0 to 100, with a higher score indicating better visual acuity. The proportion of participants who gain ≥10 ETDRS letters from baseline to year 1 will be presented.

Baseline and week 24
Proportion of Participants who Gain ≥15 ETDRS Letters from Baseline at Week 24
기간: Baseline and week 24

Participants' BCVA in the study eye will be measured using the Early Treatment of Diabetic Retinopathy (ETDRS) methodology. The ETDRS letter score ranges from 0 to 100, with a higher score indicating better visual acuity. The proportion of participants who gain ≥15 ETDRS letters from baseline to year 1 will be presented.

Baseline and week 24
Proportion of Participants who Gain ≥5 ETDRS Letters from Baseline Over Time
기간: Up to approximately 96 weeks

Participants' BCVA in the study eye will be measured using the Early Treatment of Diabetic Retinopathy (ETDRS) methodology. The ETDRS letter score ranges from 0 to 100, with a higher score indicating better visual acuity. The proportion of participants who gain ≥5 ETDRS letters from baseline over time will be presented.

Up to approximately 96 weeks
Proportion of Participants who Gain ≥10 ETDRS Letters from Baseline Over Time
기간: Up to approximately 96 weeks

Participants' BCVA in the study eye will be measured using the Early Treatment of Diabetic Retinopathy (ETDRS) methodology. The ETDRS letter score ranges from 0 to 100, with a higher score indicating better visual acuity. The proportion of participants who gain ≥10 ETDRS letters from baseline over time will be presented.

Up to approximately 96 weeks
Proportion of Participants who Gain ≥15 ETDRS Letters from Baseline Over Time
기간: Up to approximately 96 weeks

Participants' BCVA in the study eye will be measured using the Early Treatment of Diabetic Retinopathy (ETDRS) methodology. The ETDRS letter score ranges from 0 to 100, with a higher score indicating better visual acuity. The proportion of participants who gain ≥15 ETDRS letters from baseline over time will be presented.

Up to approximately 96 weeks
Proportion of Participants who Lose ≥5 ETDRS Letters from Baseline at Week 24
기간: Baseline and Week 24

Participants' BCVA in the study eye will be measured using the Early Treatment of Diabetic Retinopathy (ETDRS) methodology. The ETDRS letter score ranges from 0 to 100, with a higher score indicating better visual acuity. The proportion of participants who lose ≥5 ETDRS letters from baseline to week 24 will be presented.

Baseline and Week 24
Proportion of Participants who Lose ≥10 ETDRS Letters from Baseline at Week 24
기간: Baseline and Week 24

Participants' BCVA in the study eye will be measured using the Early Treatment of Diabetic Retinopathy (ETDRS) methodology. The ETDRS letter score ranges from 0 to 100, with a higher score indicating better visual acuity. The proportion of participants who lose ≥10 ETDRS letters from baseline to week 24 will be presented.

Baseline and Week 24
Proportion of Participants who Lose ≥15 ETDRS Letters from Baseline at Week 24
기간: Baseline and Week 24

Participants' BCVA in the study eye will be measured using the Early Treatment of Diabetic Retinopathy (ETDRS) methodology. The ETDRS letter score ranges from 0 to 100, with a higher score indicating better visual acuity. The proportion of participants who lose ≥15 ETDRS letters from baseline to week 24 will be presented.

Baseline and Week 24
Proportion of Participants who Lose ≥5 ETDRS Letters from Baseline Over Time
기간: Up to approximately 96 weeks

Participants' BCVA in the study eye will be measured using the Early Treatment of Diabetic Retinopathy (ETDRS) methodology. The ETDRS letter score ranges from 0 to 100, with a higher score indicating better visual acuity. The proportion of participants who lose ≥5 ETDRS letters from baseline over time will be presented.

Up to approximately 96 weeks
Proportion of Participants who Lose ≥10 ETDRS Letters from Baseline Over Time
기간: Up to approximately 96 weeks

Participants' BCVA in the study eye will be measured using the Early Treatment of Diabetic Retinopathy (ETDRS) methodology. The ETDRS letter score ranges from 0 to 100, with a higher score indicating better visual acuity. The proportion of participants who lose ≥10 ETDRS letters from baseline over time will be presented.

Up to approximately 96 weeks
Proportion of Participants who Lose ≥15 ETDRS Letters from Baseline Over Time
기간: Up to approximately 96 weeks

Participants' BCVA in the study eye will be measured using the Early Treatment of Diabetic Retinopathy (ETDRS) methodology. The ETDRS letter score ranges from 0 to 100, with a higher score indicating better visual acuity. The proportion of participants who lose ≥15 ETDRS letters from baseline over time will be presented.

Up to approximately 96 weeks
Proportion of Participants with BCVA Snellen Equivalent of 20/20 or Better at Week 24
기간: Week 24

Participants' BCVA in the study eye will be measured using the ETDRS methodology. The ETDRS letter score ranges from 0 to 100, with a higher score indicating better visual acuity.

The Snellen equivalent of 20/20 or better is defined as ≥84 letters correctly read in the ETDRS chart. The proportion of participants with BCVA Snellen equivalent of 20/20 or better at week 24 will be presented.

Week 24
Proportion of Participants with BCVA Snellen Equivalent of 20/20 or Better Over Time
기간: Up to approximately 96 weeks

Participants' BCVA in the study eye will be measured using the ETDRS methodology. The ETDRS letter score ranges from 0 to 100, with a higher score indicating better visual acuity.

The Snellen equivalent of 20/20 or better is defined as ≥84 letters correctly read in the ETDRS chart. The proportion of participants with BCVA Snellen equivalent of 20/20 or better over time will be presented.

Up to approximately 96 weeks
Proportion of Participants with BCVA Snellen Equivalent of 20/40 or Better at Week 24
기간: Week 24

Participants' BCVA in the study eye will be measured using the ETDRS methodology. The ETDRS letter score ranges from 0 to 100, with a higher score indicating better visual acuity.

The Snellen equivalent of 20/40 or better is defined as ≥70 letters correctly read in the ETDRS chart. The proportion of participants with BCVA Snellen equivalent of 20/40 or better at week 24 will be presented.

Week 24
Proportion of Participants with BCVA Snellen Equivalent of 20/40 or Better Over Time
기간: Up to approximately 96 weeks

Participants' BCVA in the study eye will be measured using the ETDRS methodology. The ETDRS letter score ranges from 0 to 100, with a higher score indicating better visual acuity.

The Snellen equivalent of 20/40 or better is defined as ≥70 letters correctly read in the ETDRS chart. The proportion of participants with BCVA Snellen equivalent of 20/40 or better over time will be presented.

Up to approximately 96 weeks
Proportion of Participants with BCVA Snellen Equivalent of 20/200 or Worse at Week 24
기간: Week 24

Participants' BCVA in the study eye will be measured using the ETDRS methodology. The ETDRS letter score ranges from 0 to 100, with a higher score indicating better visual acuity.

The Snellen equivalent of 20/200 or worse is defined as ≤38 letters correctly read in the ETDRS chart. The proportion of participants with BCVA Snellen equivalent of 20/200 or worse at week 24 will be presented.

Week 24
Proportion of Participants with BCVA Snellen Equivalent of 20/200 or Worse Over Time
기간: Up to approximately 96 weeks

Participants' BCVA in the study eye will be measured using the ETDRS methodology. The ETDRS letter score ranges from 0 to 100, with a higher score indicating better visual acuity.

The Snellen equivalent of 20/200 or worse is defined as ≤38 letters correctly read in the ETDRS chart. The proportion of participants with BCVA Snellen equivalent of 20/200 or worse over time will be presented.

Up to approximately 96 weeks
Change in National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) Version Composite Score Over Time
기간: Up to approximately 96 weeks

The NEI-VFQ-25 is a validated and reliable 25-item survey that measures the influence of visual disability and visual symptoms on generic health domains (emotional well-being, social functioning and task-oriented domains). The composite score ranges from 0-100 with the higher score indicating better visual function. The change in NEI-VFQ-25 version composite score over time will be presented.

Up to approximately 96 weeks
Number of Participants who Experience a Systemic Adverse Event (AE)
기간: Up to approximately 96 weeks

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who experience a systemic AE will be presented.

Up to approximately 96 weeks
Number of Participants who Experience an Ocular Adverse Event (AE)
기간: Up to approximately 96 weeks

An ocular adverse event (OAE) is defined as any untoward medical occurrence involving the eye or ocular adnexa (including eyelids, conjunctiva, lacrimal apparatus, extraocular muscles, and orbit) that:

Occurs or worsens after the first administration of the investigational product (IP) or a study-related ocular procedure, and does not necessarily have a causal relationship with the IP or procedure.

OAEs include, but are not limited to, changes in: Symptoms (e.g., ocular pain, photophobia, floaters, blurred vision), Visual function (e.g., best-corrected visual acuity [BCVA], visual field). Intraocular pressure (IOP), Anterior segment findings (e.g., conjunctival hyperemia, keratitis, anterior chamber inflammation), Posterior segment findings (e.g., vitreous inflammation, retinal hemorrhages, retinal tears or detachment, macular edema), or ocular adnexa (e.g., eyelid edema, ptosis). The number of participants who experience an ocular AE will be presented.

Up to approximately 96 weeks
Number of Participants who Discontinue Study Treatment Due to an AE
기간: Up to approximately 96 weeks

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who discontinue study treatment due to an AE will be reported.

Up to approximately 96 weeks
Number of Participants with Antidrug Antibodies (ADA) to MK-8748
기간: At designated time points (up to approximately 96 weeks)

Blood samples collected at designated timepoints will be used to determine the ADA response to MK-8748. The number of participants with ADA to MK-8748 will be presented.

At designated time points (up to approximately 96 weeks)
Maximum Plasma Concentration (Cmax) of MK-8748
기간: At designated time points (up to approximately 96 weeks)

Cmax is defined as the peak concentration over the dosing interval. Blood samples collected pre-dose and at multiple timepoints post-dose will be used to determine Cmax of MK-8748.

At designated time points (up to approximately 96 weeks)
Plasma Trough Concentration (Ctrough) of MK-8748
기간: At designated time points (up to approximately 96 weeks)

Ctrough is defined as the trough concentration. Blood samples collected pre-dose and at multiple timepoints post-dose will be used to determine Ctrough of MK-8748.

At designated time points (up to approximately 96 weeks)

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

수사관

  • 연구 책임자: Medical Director, Merck Sharp & Dohme LLC

간행물 및 유용한 링크

연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (추정된)

2026년 12월 21일

기본 완료 (추정된)

2029년 11월 19일

연구 완료 (추정된)

2029년 11월 19일

연구 등록 날짜

최초 제출

2026년 11월 16일

QC 기준을 충족하는 최초 제출

2026년 11월 16일

처음 게시됨 (실제)

2026년 11월 20일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 20일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 11월 16일

마지막으로 확인됨

2026년 11월 1일

추가 정보

이 연구와 관련된 용어

기타 연구 ID 번호

  • 8748-006
  • U1111-1342-5647 (레지스트리 식별자: UTN)
  • 2026-527378-35-00 (레지스트리 식별자: EU CT)
  • MK-8748-006 (기타 식별자: MSD)

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

예

IPD 계획 설명

https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

예

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .